TXR 1007
Alternative Names: TXR-1007Latest Information Update: 08 Sep 2021
Price :
$50 *
At a glance
- Originator Aria Pharmaceuticals
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 30 Aug 2021 TXR 1007 is available for licensing as of 30 Aug 2021. https://ariapharmaceuticals.com/partnerships/
- 26 Aug 2021 Preclinical trials in Idiopathic pulmonary fibrosis in USA (unspecified route)
- 26 Aug 2021 Pharmacodynamics data from preclinical studies in Idiopathic Pulmonary Fibrosis released by Aria Pharmaceuticals